Recent Updates
Recently added Catalysts
JSPR Negative Sentiment Score: 25/100

JASPER LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Reminds Investors a Jasper Investors to Contact the Firm Regarding Class Action Lawsuit

Key Takeaway: A class action lawsuit has been initiated against Jasper Therapeutics, Inc. by Bragar Eagel & Squire, P.C. The lawsuit concerns allegations of materially false and misleading statements by the company regarding its business practices and manufacturing compliance. The allegations suggest that Jasper lacked proper controls over third-party manufacturers, potentially affecting the outcomes of clinical trials. Investors impacted during the defined class period are encouraged to contact the law firm for representation.

Market Sentiment Analysis

CONCERNS & RISKS

  • Class action lawsuit filed against Jasper Therapeutics for misleading statements.
  • Allegations of lack of necessary controls and procedures for manufacturing compliance.
  • Increased risk impacting the regulatory and commercial prospects of the company’s products.
  • Potential for disruptive cost-reduction measures affecting company stability.

Full Press Release Details

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Jasper (JSPR) To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Jasper between November 30, 2023 and July 3, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
Click here to participate in the action.
NEW YORK, Oct. 04, 2025 (GLOBE NEWSWIRE) --
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Jasper Therapeutics, Inc. (“Jasper” or the “Company”) (NASDAQ:JSPR) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired Jasper securities between November 30, 2023 and July 3, 2025, both dates inclusive (the “Class Period”).
Investors have until November 18, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Jasper lacked the controls and procedures necessary to ensure that the third-party manufacturers on which it relied were manufacturing products in full accordance with cGMP regulations and otherwise suitable for use in clinical trials; (ii) the foregoing failure increased the risk that results of ongoing studies would be confounded, thereby negatively impacting the regulatory and commercial prospects of the Company's products, including briquilimab; (iii) the foregoing increased the likelihood of disruptive cost-reduction measures; (iv) accordingly, the Company's business and/or financial prospects, as well as briquilimab's clinical and/or commercial prospects, were overstated; and (v) as a result, Defendants' public statements were materially false and misleading at all relevant times.
If you purchased or otherwise acquired Jasper shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Tags

Bragar Eagel & Squire

Frequently Asked Questions

Who can join the Jasper class action lawsuit?

Individuals or entities who bought Jasper securities between November 30, 2023, and July 3, 2025, can join.

What is the deadline to apply as lead plaintiff?

Investors must apply by November 18, 2025, to be appointed as lead plaintiff.

What are the allegations against Jasper Therapeutics?

The lawsuit claims Jasper made false statements about its business and compliance.

How can I contact Bragar Eagel & Squire for assistance?

You can reach them by phone at (212) 355-4648 or via email at investigations@bespc.com.

Is there any cost to discuss my case?

There is no cost or obligation for investors to discuss their legal options.

Last updated: Oct 4, 2025